Ceftazidime-avibactam Activity Against Multidrug-resistant Pseudomonas Aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2015 Apr 8

PMID 25845861

Citations 35

Authors

Helio S Sader

Mariana Castanheira

Rodrigo E Mendes

Robert K Flamm

David J Farrell

Ronald N Jones

Affiliations

Soon will be listed here.

Abstract

Pseudomonas aeruginosa isolates (n = 3,902) from 75 U.S. medical centers were tested against ceftazidime-avibactam and comparator agents by the reference broth microdilution method. Overall, 96.9% of the strains were susceptible (MIC, ≤8 μg/ml) to ceftazidime-avibactam, while the rates of susceptibility for ceftazidime, meropenem, and piperacillin-tazobactam were 83.8, 81.9, and 78.5%, respectively. Multidrug-resistant and extensively drug-resistant phenotypes were observed in 14.9 and 8.7% of the strains, respectively, and 81.0 and 73.7% of the strains were susceptible to ceftazidime-avibactam, respectively.

Citing Articles

Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.

Wang Y, Sholeh M, Yang L, Shakourzadeh M, Beig M, Azizian K Antimicrob Resist Infect Control. 2025; 14(1):10.

PMID: 39934901 PMC: 11818042. DOI: 10.1186/s13756-025-01518-5.

Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.

Buyukyanbolu E, Genc L, Cyr E, Karakus M, Comert F, Otlu B Eur J Clin Microbiol Infect Dis. 2024; 43(9):1787-1794.

PMID: 38995343 DOI: 10.1007/s10096-024-04896-7.

Crystal structure of the class A extended-spectrum β-lactamase CTX-M-96 in complex with relebactam at 1.03 Angstrom resolution.

Ghiglione B, Rodriguez M, Penzotti P, Bethel C, Gutkind G, Bonomo R Antimicrob Agents Chemother. 2024; 68(8):e0172123.

PMID: 38990013 PMC: 11304709. DOI: 10.1128/aac.01721-23.

Cephalosporin resistance, tolerance, and approaches to improve their activities.

Araten A, Brooks R, Choi S, Esguerra L, Savchyn D, Wu E J Antibiot (Tokyo). 2023; 77(3):135-146.

PMID: 38114565 DOI: 10.1038/s41429-023-00687-y.

Virtual Screening of Potential RoxS Inhibitors and Evaluation of Their Antimicrobial Activity in Combination with Antibiotics against Clinically Resistant Bacteria.

Huang Y, Li J, Liang T, Zhao Z, Xu J, Chen W Antibiotics (Basel). 2023; 12(9).

PMID: 37760718 PMC: 10525716. DOI: 10.3390/antibiotics12091422.

References

Livermore D . Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis. 2002; 34(5):634-40. DOI: 10.1086/338782. View

Richards D, Brogden R . Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985; 29(2):105-61. DOI: 10.2165/00003495-198529020-00002. View

Lister P, Wolter D, Hanson N . Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009; 22(4):582-610. PMC: 2772362. DOI: 10.1128/CMR.00040-09. View

Mushtaq S, Warner M, Livermore D . In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother. 2010; 65(11):2376-81. DOI: 10.1093/jac/dkq306. View

Walkty A, DeCorby M, Lagace-Wiens P, Karlowsky J, Hoban D, Zhanel G . In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother. 2011; 55(6):2992-4. PMC: 3101411. DOI: 10.1128/AAC.01696-10. View

Breidenstein E, de la Fuente-Nunez C, Hancock R . Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011; 19(8):419-26. DOI: 10.1016/j.tim.2011.04.005. View

Coleman K . Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr Opin Microbiol. 2011; 14(5):550-5. DOI: 10.1016/j.mib.2011.07.026. View

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

Sievert D, Ricks P, Edwards J, Schneider A, Patel J, Srinivasan A . Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2012; 34(1):1-14. DOI: 10.1086/668770. View

10.

Shlaes D . New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci. 2013; 1277:105-14. DOI: 10.1111/nyas.12010. View

11.

Sader H, Castanheira M, Flamm R, Farrell D, Jones R . Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother. 2014; 58(3):1684-92. PMC: 3957905. DOI: 10.1128/AAC.02429-13. View

12.

Castanheira M, Deshpande L, Costello A, Davies T, Jones R . Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. J Antimicrob Chemother. 2014; 69(7):1804-14. DOI: 10.1093/jac/dku048. View

13.

Keepers T, Gomez M, Celeri C, Nichols W, Krause K . Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2014; 58(9):5297-305. PMC: 4135815. DOI: 10.1128/AAC.02894-14. View

14.

Lahiri S, Johnstone M, Ross P, McLaughlin R, Olivier N, Alm R . Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother. 2014; 58(10):5704-13. PMC: 4187909. DOI: 10.1128/AAC.03057-14. View

15.

Castanheira M, Mills J, Farrell D, Jones R . Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother. 2014; 58(11):6844-50. PMC: 4249397. DOI: 10.1128/AAC.03681-14. View

16.

Flamm R, Stone G, Sader H, Jones R, Nichols W . Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother. 2013; 26(6):333-8. DOI: 10.1179/1973947813Y.0000000145. View